Evaluation of soluble Fms-like thyroxine kinase-1 and anti-endothelial antibodies in patients with acute coronary syndrome in the post-COVID period

Objective: to evaluate the role of soluble fms-like thyroxine kinase-1 and endothelial factor in patients with acute coronary syndrome in the post-COVID period. Material and methods. The study included 118 patients (including 57 women and 61 men) with acute coronary syndrome and COVID-19 history. Soluble fms-like thyroxine kinase-1 and endothelial factor were determined in all patients. The comparison group consisted of 121 patients with acute coronary syndrome without COVID-19.